Status:
COMPLETED
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
Lead Sponsor:
Tanabe Pharma Corporation
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
20-65 years
Phase:
PHASE3
Brief Summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who did not respond to previous treatment.
Eligibility Criteria
Inclusion
- Genotype 2, chronic hepatitis C
- Non-responders (patient who did not respond to previous treatment)
- Able and willing to follow contraception requirements
Exclusion
- Cirrhosis of the liver or hepatic failure
- Hepatitis B surface antigen-positive or HIV antibodies-positive
- History of, or concurrent hepatocellular carcinoma
- History of, or concurrent depression, schizophrenia,; or suicide attempt in the past
- Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01468584
Start Date
November 1 2011
End Date
September 1 2013
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toranomon Hospital
Minato-ku, Tokyo, Japan